[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563975-105":53,"doc-detail-563975-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","medications-for-weight-loss-marketed-in-canada-july-2025-update","Medications for Weight Loss Marketed in Canada - July 2025 update","","A Canada-focused reference table summarizing marketed weight-loss medications with key details for chronic weight management. For each therapy, it lists dosage forms and strengths, approximate annual cost and PharmaCare benefit status, and summarizes Health Canada guidance including indications by eligible age and BMI criteria, contraindications, and critical dosing parameters. It also covers administration instructions, titration schedules, and comparative dose-response notes, along with source footnotes to support pricing and coverage context.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/medications-for-weight-loss-marketed-in-canada-july-2025-update/563975/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/medications-for-weight-loss-marketed-in-canada-july-2025-update/563975.png","ImageObject",442,249,{"name":88,"@type":89},"Jacob","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-16","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":9},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"Which age and BMI criteria are used for weight-loss indication eligibility in Canada?","Question",{"text":108,"@type":109},"For tirzepatide and most GLP-1 therapies, indications list adults aged ≥18 with BMI ≥30 kg/m2 or ≥27 kg/m2 plus a weight-related comorbidity. Semaglutide and liraglutide additionally include specific adolescent criteria for ages 12–17 based on body weight, BMI percentile, and inadequate response to diet and activity alone.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"What are the main contraindications shared across several listed medications?",{"text":113,"@type":109},"Common contraindications include personal or family history of medullary thyroid cancer and Multiple Endocrine Neoplasia syndrome type 2, plus pregnancy and breastfeeding. For naltrexone/bupropion, additional contraindications include opioid use or withdrawal, uncontrolled hypertension, seizure disorder, eating disorders, certain drug interactions (e.g., MAOIs), severe hepatic impairment, and end-stage renal failure.",{"name":115,"@type":106,"acceptedAnswer":116},"How do dosing and titration schedules typically work for these medications?",{"text":117,"@type":109},"The table provides drug-specific initiation doses followed by titration at defined intervals (e.g., weekly or every 4 weeks) until a maintenance dose is reached. It also specifies administration routes (such as subcutaneous injection for tirzepatide/GLP-1 agents) and practical guidance such as rotating injection sites and timing (e.g., orlistat with meals containing fat).","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},563975,1792112561,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":9,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":9,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":4},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Medications for Weight Loss Marketed in Canada (July 2025 update)  \n\n| Generic/brand, strengths, dosage forms,1 cost,2 coverage3 | Health Canada chronic weight management indications*, contraindications, dosage considerations\u003Cbr>indication, initial dosing, titration, dose response, maximum dose, administration1 |  |\n| --- | --- | --- |\n| GLUCAGON-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) & GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP1) |  |  |\n| tirzepatide\u003Cbr>ZEPBOUND\u003Cbr>2.5, 5, 7.5, 10, 12.5, 15 mg/dose multidose prefilled pens\u003Cbr>PharmaCare: non benefit\u003Cbr>Annual cost: $10,600 | Indications | ▪ ages ≥ 18 years: BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight-related comorbidity |\n|  | Contraindications | ▪ personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, breastfeeding |\n|  | Initial dosing | ▪ 2.5 mg subcutaneously once weekly for 4 weeks |\n|  | Dose response | ▪ 10 mg vs. 5 mg: 5% additional weight loss; 15 mg vs. 10 mg: 1% additional weight loss |\n|  | Dose titration | ▪ every 4 weeks in 2.5 mg increments up to 5, 10 or 15 mg/week |\n|  | Administration | ▪ subcutaneous injection into abdomen, thigh or upper arm (rotate sites with each dose) |\n| GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS (GLP1a) |  |  |\n| semaglutide\u003Cbr>WEGOVY\u003Cbr>0. 25, 0.5, 1, 1.7, 2.4 mg/dose multidose prefilled pens\u003Cbr>PharmaCare: non benefit\u003Cbr>Annual cost: $5600 | Indications | ▪ ages ≥ 18 years: BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight-related comorbidity\u003Cbr>▪ ages 12 – 17 years: body weight > 60 kg and BMI ≥ 95th percentile for age and sex and inadequate response to reduced calorie diet and physical activity alone |\n|  | Contraindications | ▪ personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, breastfeeding |\n|  | Initial dosing | ▪ 0.25 mg subcutaneously once weekly for 4 weeks |\n|  | Dose response | ▪ 2.4 mg vs. 1 mg: 3% additional weight loss; 2.4 mg vs. 1.7 mg: 4% additional weight loss |\n|  | Dose titration | ▪ every 4 weeks to doses of 0 .5, 1, 1.7 mg until maintenance dose of 2.4 mg/week reached |\n|  | Administration | ▪ subcutaneous injection into abdomen, thigh or upper arm (rotate sites with each dose) |\n| liraglutide\u003Cbr>SAXENDA\u003Cbr>0.6, 1. 2, 1.8, 2.4, 3 mg/dose multidose prefilled pens\u003Cbr>PharmaCare: non benefit\u003Cbr>Approx. annual cost: $5600 | Indications | ▪ ages ≥ 18 years: BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with ≥ 1 weight-related comorbidity and failed previous weight management intervention\u003Cbr>▪ ages 12 – 17 years: body weight > 60 kg and BMI corresponding to ≥ 30 kg/m2 for adults and inadequate response to reduced calorie diet and physical activity alone |\n|  | Contraindications | ▪ personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, breastfeeding |\n|  | Initial dosing | ▪ 0.6 mg subcutaneously once daily for 1 week |\n|  | Dose response | ▪ 3 mg vs. 1.8 mg: 1% additional weight loss |\n|  | Dose titration | ▪ every week to doses of 1. 2, 1.8, 2.4 mg until maintenance dose of 3 mg/day reached |\n|  | Administration | ▪ subcutaneous injection into abdomen, thigh or upper arm (rotate sites with each dose) |\n| OPIOID ANTAGONIST/ANTIDEPRESSANT COMBINATIONS |  |  |\n| naltrexone/bupropion\u003Cbr>CONTRAVE\u003Cbr>8/90 mg extended-release tablets\u003Cbr>PharmaCare: non benefit\u003Cbr>Approx. annual cost: $3700 | Indications | ▪ ages ≥ 18 years: BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with ≥ 1 weight-related comorbidity |\n|  | Contraindications | ▪ opioid use (agonist or partial agonist, including tramadol), opioid withdrawal, uncontrolled hypertension, seizure disorder, bulimia, anorexia nervosa, concomitant MAOIs, thioridazine, or other bupropion containing products (Wellbutrin®, Zyban®), severe hepatic impairment, end-stage renal failure, pregnancy, abrupt discontinuation of alcohol, benzodiazepines or other sedatives and antiepileptic drugs |\n|  | Initial dosing | ▪ 8/90 mg tablet orally once ","cbCaiivGASsU4fUo","https://ap.wps.com/l/cbCaiivGASsU4fUo","pdf",276975,"English","# Medication overview\n## GLP-1 and related agonists\n## Opioid antagonist/antidepressant combinations\n## Gastrointestinal lipase inhibitors\n## Notes and sources","[{\"question\":\"Which age and BMI criteria are used for weight-loss indication eligibility in Canada?\",\"answer\":\"For tirzepatide and most GLP-1 therapies, indications list adults aged ≥18 with BMI ≥30 kg/m2 or ≥27 kg/m2 plus a weight-related comorbidity. Semaglutide and liraglutide additionally include specific adolescent criteria for ages 12–17 based on body weight, BMI percentile, and inadequate response to diet and activity alone.\"},{\"question\":\"What are the main contraindications shared across several listed medications?\",\"answer\":\"Common contraindications include personal or family history of medullary thyroid cancer and Multiple Endocrine Neoplasia syndrome type 2, plus pregnancy and breastfeeding. For naltrexone/bupropion, additional contraindications include opioid use or withdrawal, uncontrolled hypertension, seizure disorder, eating disorders, certain drug interactions (e.g., MAOIs), severe hepatic impairment, and end-stage renal failure.\"},{\"question\":\"How do dosing and titration schedules typically work for these medications?\",\"answer\":\"The table provides drug-specific initiation doses followed by titration at defined intervals (e.g., weekly or every 4 weeks) until a maintenance dose is reached. It also specifies administration routes (such as subcutaneous injection for tirzepatide/GLP-1 agents) and practical guidance such as rotating injection sites and timing (e.g., orlistat with meals containing fat).\"}]","Medications for Weight Loss Marketed in Canada - July 2025 update | PDF",1791839632]